By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Metabolon said today it is using its metabolomic technology to discover therapeutic targets and biomarkers under a collaboration with Takeda Pharmaceutical.

Under the multi-year deal, Metabolon will apply its analytical platform and software to discover and validate targets and to identify novel pharmacodynamic biomarkers for translation into the clinic.

Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.